美国法官周一驳回了诺和诺德要求阻止礼来继续投放减肥药广告的请求，裁定这家丹麦药企认为虚假且具有误导性的广告可以继续播放。
US judge won't block Eli Lilly ads for weight-loss drugs, rules against Novo Nordisk By Jonathan Stempel Oct 26 - A US judge on Monday rejected Novo Nordisk's request to block Eli Lilly from continuing weight-loss drug s that the Danish drugmaker considered false and misleading.
诺和诺德曾请求法院发布初步禁令，在案件审理期间叫停礼来的广告宣传。
Novo Nordisk had requested a preliminary injunction to halt Eli Lilly's advertising while the case proceeded.
新泽西州特伦顿联邦地区法官扎希德·库雷希驳回了该请求，称诺和诺德关于将遭受不可挽回损害的主张“不足以支持其寻求的非常规救济”。减肥药已成为大型制药公司的主要业务。美国是极少数允许处方药直接面向消费者广告的国家之一。
US District Judge Zahid Quraishi in Trenton, New Jersey rejected that request, calling Novo Nordisk's claim of irreparable harm "inadequate to warrant the extraordinary relief it seeks." Weight-loss drugs have become major businesses for large pharmaceutical companies. The United States is one of only a handful of countries that allow direct-to-consumer advertising of prescription medicines.
诺和诺德于7月起诉礼来，称后者针对肥胖症药物Zepbound（捷邦）和糖尿病治疗药物Mounjaro（蒙佳诺）的广告，将这些产品的较高剂量与诺和诺德Wegovy（卫戈）和Ozempic（奥森比克）的较低剂量进行对比。
Novo Nordisk sued Eli Lilly in July, saying ads for the obesity drug Zepbound and diabetes treatment Mounjaro compared higher doses of those products with lower doses of Novo Nordisk's Wegovy and Ozempic.
诺和诺德表示，广告宣称礼来药物更优越，违反了虚假广告和不正当竞争法，足以证明发布禁令的正当性。礼来否认有任何不当行为。
The ads claiming that Eli Lilly drugs were superior violated false advertising and unfair competition laws, justifying an injunction, Novo Nordisk said. Eli Lilly has denied wrongdoing.
诺和诺德正努力夺回其注射型肥胖症药物在美国的市场份额，该市场预计到本世纪末将超过1000亿美元。库雷希法官在8月27日和28日举行听证会后作出裁决。
Novo Nordisk is working to regain market share in the United States for its injectable obesity drugs, a market projected to exceed $100 billion by the end of the decade. Quraishi ruled following a hearing on August 27 and 28.